- Home
- TEM vs RGEN Comparison
TEM vs RGEN Comparison
Compare TEM & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEM
- RGEN
- Stock Information
- Founded
- TEM 2015
- RGEN 1981
- Country
- TEM United States
- RGEN United States
- Employees
- TEM N/A
- RGEN N/A
- Industry
- TEM
- RGEN Medical/Dental Instruments
- Sector
- TEM
- RGEN Health Care
- Exchange
- TEM NYSE
- RGEN Nasdaq
- Market Cap
- TEM 6.3B
- RGEN 7.6B
- IPO Year
- TEM 2024
- RGEN N/A
- Fundamental
- Price
- TEM $31.83
- RGEN $156.55
- Analyst Decision
- TEM Buy
- RGEN Buy
- Analyst Count
- TEM 11
- RGEN 12
- Target Price
- TEM $57.20
- RGEN $187.44
- AVG Volume (30 Days)
- TEM 4.0M
- RGEN 470.1K
- Earning Date
- TEM 02-17-2025
- RGEN 02-19-2025
- Dividend Yield
- TEM N/A
- RGEN N/A
- EPS Growth
- TEM N/A
- RGEN N/A
- EPS
- TEM N/A
- RGEN N/A
- Revenue
- TEM $640,442,000.00
- RGEN $633,513,000.00
- Revenue This Year
- TEM $32.70
- RGEN $2.28
- Revenue Next Year
- TEM $38.77
- RGEN $9.88
- P/E Ratio
- TEM N/A
- RGEN N/A
- Revenue Growth
- TEM 32.13
- RGEN N/A
- 52 Week Low
- TEM $22.89
- RGEN $113.50
- 52 Week High
- TEM $79.49
- RGEN $211.13
- Technical
- Relative Strength Index (RSI)
- TEM N/A
- RGEN 60.07
- Support Level
- TEM N/A
- RGEN $149.15
- Resistance Level
- TEM N/A
- RGEN $160.64
- Average True Range (ATR)
- TEM 0.00
- RGEN 5.96
- MACD
- TEM 0.00
- RGEN 0.91
- Stochastic Oscillator
- TEM 0.00
- RGEN 79.57
About TEM TEMPUS AI INC
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.